Empower the body, cure the disease

Mnemo Therapeutics is a Paris-based biotechnology company driven to create powerful immunotherapies by improving the body’s ability to detect and eradicate cancer. The paucity of actionable cancer-specific targets creates significant challenges in the field of immuno-oncology. To address this, Mnemo has developed a combination of in-silico and wet-lab pipelines to uncover new tumour-specific targets (called E-antigens) derived from the unexploited dark genome, and to develop multiple therapeutic modalities (i.e. cell therapy, TCE, ADC, vaccine) targeting these E-antigens. Mnemo is currently pursuing several discovery campaigns for E-antigens, with a plan to develop its proprietary tumour-specific targets and therapeutics portfolio together with its historic founding partners.